PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028344
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2028344
Sickle Cell Disease Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of sickle cell disease (SCD) treatment Market
The global sickle cell disease (SCD) treatment market was valued at USD 3.94 billion in 2025 and increased to USD 4.73 billion in 2026, with projections indicating it will reach USD 20.47 billion by 2034. The market is experiencing strong growth due to rising disease prevalence, increasing awareness, and advancements in treatment options. The United States dominated the market with a 63.35% share in 2025, supported by strong healthcare infrastructure, high diagnosis rates, and continuous drug development initiatives.
Sickle cell disease is a genetic blood disorder that affects hemoglobin, leading to abnormal red blood cells, reduced oxygen flow, and complications such as anemia, pain crises, and organ damage. Treatment approaches include blood transfusion, pharmacotherapy, and bone marrow transplantation, with increasing focus on advanced therapies.
Market Trends
One of the most significant trends in the market is the growing adoption of gene therapy. Gene therapy targets the root cause of the disease by correcting genetic mutations, offering the potential for long-term or permanent treatment. Several clinical trials, including CRISPR-based therapies, are progressing and showing promising outcomes.
Another key trend is the increasing focus on innovative drug development. Pharmaceutical companies are investing heavily in research and development to introduce new therapies that reduce complications such as vaso-occlusive crises (VOCs). Recently approved drugs and pipeline candidates are expected to transform treatment standards.
Additionally, there is a rising emphasis on personalized medicine and targeted therapies, which aim to improve patient outcomes and reduce treatment-related complications.
Driving Factors
The market is primarily driven by the increasing prevalence of sickle cell disease globally. According to estimates, millions of individuals are affected worldwide, with a significant patient population in regions such as Africa, the U.S., and India. In the U.S. alone, approximately 100,000 individuals are affected by SCD.
Another major driver is the growing severity and frequency of disease complications, such as vaso-occlusive crises. Patients can experience multiple episodes annually, increasing the demand for effective treatment solutions and emergency care.
The introduction of novel therapies and regulatory support is also accelerating market growth. Agencies such as the U.S. FDA and European Medicines Agency are providing fast-track approvals for innovative drugs, encouraging pharmaceutical companies to expand their product pipelines.
Furthermore, increasing awareness and government initiatives aimed at improving diagnosis and treatment access are contributing to market expansion.
Restraining Factors
Despite strong growth prospects, the market faces challenges due to the limited availability of treatment options in developing regions. Many countries lack access to advanced therapies and essential medications such as hydroxyurea.
Another major restraint is the high cost of treatment, particularly for advanced therapies such as gene therapy and bone marrow transplantation, which limits accessibility for a large patient population.
Additionally, lack of awareness and inadequate healthcare infrastructure in certain regions continue to hinder market growth.
Segmentation Analysis
By treatment modality, the market is segmented into blood transfusion, bone marrow transplant, and pharmacotherapy. The blood transfusion segment holds the largest share due to its effectiveness in managing severe complications such as stroke. However, pharmacotherapy is expected to grow rapidly due to the introduction of new drugs and increasing adoption of advanced treatments.
By end-user, the market includes hospitals, specialty clinics, and others. Hospitals dominate the segment due to the high number of patient admissions and availability of advanced treatment facilities. Specialty clinics are also gaining traction due to specialized care and increasing patient preference.
Regional Analysis
The United States leads the global market with a valuation of USD 2.49 billion in 2025 and USD 3.00 billion in 2026, driven by strong research activities, high treatment accessibility, and continuous product approvals.
Europe holds a significant share, supported by favorable reimbursement policies and increasing patient awareness. Countries in the region are focusing on expanding treatment accessibility and improving healthcare infrastructure.
The Middle East & Africa region is expected to witness notable growth due to the high prevalence of SCD and increasing awareness initiatives. However, limited healthcare resources remain a challenge.
Key Industry Players and Developments
Major players in the market include Pfizer Inc. (Global Blood Therapeutics), Novartis AG, Emmaus Medical, bluebird bio Inc., Agios Pharmaceuticals, and Bristol-Myers Squibb Company. These companies are focusing on developing innovative therapies and expanding their global presence.
Recent developments include strategic partnerships, product approvals, and expansion programs aimed at improving treatment accessibility and addressing unmet medical needs.
Conclusion
The sickle cell disease treatment market is projected to grow from USD 3.94 billion in 2025 to USD 20.47 billion by 2034, driven by rising disease prevalence, advancements in gene therapy, and increasing investment in drug development. While challenges such as high treatment costs and limited access in developing regions persist, ongoing innovation and regulatory support are expected to significantly transform the treatment landscape in the coming years.
Segmentation By Treatment Modality, End-user, and Geography
By Treatment Modality * Bone Marrow Transplant
- Blood Transfusion
- Pharmacotherapy
- Hydroxyurea
- Branded Products
- Endari
- Adakveo
- Oxbryta
- Zynteglo
- PYRUKYND (Mitapivat)
- CTX001
- Inclacumab
- MGTA-145
- Vamifeport (VIT-2763)
- ALXN1820
- FT-4202
- GBT021601
By End-user
Hospitals
- Specialty Clinics
- Others
By Geography * U.S. (By Treatment Modality and End-user)
- Europe (By Treatment Modality, End-user, and Country/Sub-region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Rest of the World (By Treatment Modality, End-user, and Country/Sub-region)
- India
- China
- Japan
- GCC Countries
- Rest of ROW
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Prevalence of Sickle Cell Disease, For Key Countries/ Regions, 2025
- 4.2. Overview - Branded Drugs (Marketed)
- 4.3. Pipeline Analysis, Key Players
- 4.4. New Product Launches
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnership; etc.)
- 4.6. Impact of COVID-19 on the Market
5. Global Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Treatment Modality
- 5.1.1. Bone Marrow Transplant
- 5.1.2. Blood Transfusion
- 5.1.3. Pharmacotherapy
- 5.1.3.1. Hydroxyurea
- 5.1.3.2. Branded Products
- 5.1.3.2.1. Endari
- 5.1.3.2.2. Adakveo
- 5.1.3.2.3. Oxbryta
- 5.1.3.2.4. PYRUKYND (Mitapivat)
- 5.1.3.2.5. Zynteglo
- 5.1.3.2.6. CTX001
- 5.1.3.2.7. Inclacumab
- 5.1.3.2.8. Vamifeport (VIT-2763)
- 5.1.3.2.9. ALXN1820
- 5.1.3.2.10. MGTA-145
- 5.1.3.2.11. FT-4202
- 5.1.3.2.12. GBT021601
- 5.2. Market Analysis, Insights and Forecast - By End-user
- 5.2.1. Hospitals
- 5.2.2. Specialty Clinics
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast - By Country/Region
- 5.3.1. U.S.
- 5.3.2. Europe
- 5.3.3. Rest of the World
6. U.S. Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Treatment Modality
- 6.1.1. Bone Marrow Transplant
- 6.1.2. Blood Transfusion
- 6.1.3. Pharmacotherapy
- 6.1.3.1. Hydroxyurea
- 6.1.3.2. Branded Products
- 6.1.3.2.1. Endari
- 6.1.3.2.2. Adakveo
- 6.1.3.2.3. Oxbryta
- 6.1.3.2.4. PYRUKYND (Mitapivat)
- 6.1.3.2.5. Zynteglo
- 6.1.3.2.6. CTX001
- 6.1.3.2.7. Inclacumab
- 6.1.3.2.8. Vamifeport (VIT-2763)
- 6.1.3.2.9. ALXN1820
- 6.1.3.2.10. MGTA-145
- 6.1.3.2.11. FT-4202
- 6.1.3.2.12. GBT021601
- 6.2. Market Analysis, Insights and Forecast - By End-user
- 6.2.1. Hospitals
- 6.2.2. Specialty Clinics
- 6.2.3. Others
7. Europe Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Treatment Modality
- 7.1.1. Bone Marrow Transplant
- 7.1.2. Blood Transfusion
- 7.1.3. Pharmacotherapy
- 7.1.3.1. Hydroxyurea
- 7.1.3.2. Branded Products
- 7.1.3.2.1. Endari
- 7.1.3.2.2. Adakveo
- 7.1.3.2.3. Oxbryta
- 7.1.3.2.4. PYRUKYND (Mitapivat)
- 7.1.3.2.5. Zynteglo
- 7.1.3.2.6. CTX001
- 7.1.3.2.7. Inclacumab
- 7.1.3.2.8. Vamifeport (VIT-2763)
- 7.1.3.2.9. ALXN1820
- 7.1.3.2.10. MGTA-145
- 7.1.3.2.11. FT-4202
- 7.1.3.2.12. GBT021601
- 7.2. Market Analysis, Insights and Forecast - By End-user
- 7.2.1. Hospitals
- 7.2.2. Specialty Clinics
- 7.2.3. Others
8. Rest of the World Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Treatment Modality
- 8.1.1. Bone Marrow Transplant
- 8.1.2. Blood Transfusion
- 8.1.3. Pharmacotherapy
- 8.1.3.1. Hydroxyurea
- 8.1.3.2. Branded Products
- 8.1.3.2.1. Endari
- 8.1.3.2.2. Adakveo
- 8.1.3.2.3. Oxbryta
- 8.1.3.2.4. PYRUKYND (Mitapivat)
- 8.1.3.2.5. Zynteglo
- 8.1.3.2.6. CTX001
- 8.1.3.2.7. Inclacumab
- 8.1.3.2.8. Vamifeport (VIT-2763)
- 8.1.3.2.9. ALXN1820
- 8.1.3.2.10. MGTA-145
- 8.1.3.2.11. FT-4202
- 8.1.3.2.12. GBT021601
- 8.2. Market Analysis, Insights and Forecast - By End-user
- 8.2.1. Hospitals
- 8.2.2. Specialty Clinics
- 8.2.3. Others
9. Competitive Analysis
- 9.1. Global Market Share Analysis (2025)
- 9.2. Company Profiles
- 9.2.1. Bristol-Myers Squibb Company
- 9.2.1.1. Overview
- 9.2.1.2. Product
- 9.2.1.3. SWOT Analysis
- 9.2.1.4. Recent Developments
- 9.2.1.5. Strategies
- 9.2.1.6. financials (Based on Availability)
- 9.2.2. Addmedica
- 9.2.2.1. Overview
- 9.2.2.2. Product
- 9.2.2.3. SWOT Analysis
- 9.2.2.4. Recent Developments
- 9.2.2.5. Strategies
- 9.2.2.6. financials (Based on Availability)
- 9.2.3. Novartis AG
- 9.2.3.1. Overview
- 9.2.3.2. Product
- 9.2.3.3. SWOT Analysis
- 9.2.3.4. Recent Developments
- 9.2.3.5. Strategies
- 9.2.3.6. financials (Based on Availability)
- 9.2.4. Global Blood Therapeutics, Inc. (Pfizer Inc.)
- 9.2.4.1. Overview
- 9.2.4.2. Product
- 9.2.4.3. SWOT Analysis
- 9.2.4.4. Recent Developments
- 9.2.4.5. Strategies
- 9.2.4.6. financials (Based on Availability)
- 9.2.5. Emmaus Medical, Inc.
- 9.2.5.1. Overview
- 9.2.5.2. Product
- 9.2.5.3. SWOT Analysis
- 9.2.5.4. Recent Developments
- 9.2.5.5. Strategies
- 9.2.5.6. financials (Based on Availability)
- 9.2.6. bluebird bio Inc.
- 9.2.6.1. Overview
- 9.2.6.2. Product
- 9.2.6.3. SWOT Analysis
- 9.2.6.4. Recent Developments
- 9.2.6.5. Strategies
- 9.2.6.6. financials (Based on Availability)
- 9.2.7. Agios Pharmaceuticals, Inc.
- 9.2.7.1. Overview
- 9.2.7.2. Product
- 9.2.7.3. SWOT Analysis
- 9.2.7.4. Recent Developments
- 9.2.7.5. Strategies
- 9.2.7.6. financials (Based on Availability)
- 9.2.1. Bristol-Myers Squibb Company
List of Tables
- Table 01: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2021-2034
- Table 02: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2021-2034
- Table 03: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2021-2034
- Table 04: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2021-2034
- Table 05: Global Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Geography, 2021-2034
- Table 06: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2021-2034
- Table 07: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2021-2034
- Table 08: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2021-2034
- Table 09: U.S. Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2021-2034
- Table 10: Europe Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2021-2034
- Table 11: Europe Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2021-2034
- Table 12: Europe Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2021-2034
- Table 13: Europe Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2021-2034
- Table 14: Rest of the World Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Treatment Modality, 2021-2034
- Table 15: Rest of the World Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Pharmacotherapy, 2021-2034
- Table 16: Rest of the World Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By Branded Products, 2021-2034
- Table 17: Rest of the World Sickle Cell Disease Treatment Market Revenue (USD billion) Forecast, By End-user, 2021-2034
List of Figures
- Figure 01: Global Sickle Cell Disease Treatment Market Revenue Breakdown (USD billion, %) by Geography, 2025 & 2034
- Figure 02: Global Sickle Cell Disease Treatment Market Value Share (%), By Treatment Modality, 2025 & 2034
- Figure 03: Global Sickle Cell Disease Treatment Market Value Share (%), By End-user, 2025 & 2034
- Figure 04: Global Sickle Cell Disease Treatment Market Value Share (%), By Geography, 2025 & 2034
- Figure 05: U.S. Sickle Cell Disease Treatment Market Value (USD billion), by Treatment Modality, 2025 & 2034
- Figure 06: U.S. Sickle Cell Disease Treatment Market Value Share (%), by Treatment Modality, 2025
- Figure 07: U.S. Sickle Cell Disease Treatment Market Value (USD billion), by End-user, 2025 & 2034
- Figure 08: U.S. Sickle Cell Disease Treatment Market Value Share (%), by End-user, 2025
- Figure 09: Europe Sickle Cell Disease Treatment Market Value (USD billion), by Treatment Modality, 2025 & 2034
- Figure 10: Europe Sickle Cell Disease Treatment Market Value Share (%), by Treatment Modality, 2025
- Figure 11: Europe Sickle Cell Disease Treatment Market Value (USD billion), by End-user, 2025 & 2034
- Figure 12: Europe Sickle Cell Disease Treatment Market Value Share (%), by End-user, 2025
- Figure 13: Rest of the World Sickle Cell Disease Treatment Market Value (USD billion), by Treatment Modality, 2025 & 2034
- Figure 14: Rest of the World Sickle Cell Disease Treatment Market Value Share (%), by Treatment Modality, 2025
- Figure 15: Rest of the World Sickle Cell Disease Treatment Market Value (USD billion), by End-user, 2025 & 2034
- Figure 16: Rest of the World Sickle Cell Disease Treatment Market Value Share (%), by End-user, 2025
- Figure 17: Global Sickle Cell Disease Treatment Market Share (%), by Company, 2025
